- Home
- KPTI vs NVCT Comparison
KPTI vs NVCT Comparison
Compare KPTI & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- NVCT
- Stock Information
- Founded
- KPTI 2008
- NVCT 2020
- Country
- KPTI United States
- NVCT United States
- Employees
- KPTI N/A
- NVCT N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- KPTI Health Care
- NVCT Health Care
- Exchange
- KPTI Nasdaq
- NVCT Nasdaq
- Market Cap
- KPTI 121.2M
- NVCT 119.4M
- IPO Year
- KPTI 2013
- NVCT 2022
- Fundamental
- Price
- KPTI $0.85
- NVCT $6.50
- Analyst Decision
- KPTI Strong Buy
- NVCT Strong Buy
- Analyst Count
- KPTI 4
- NVCT 1
- Target Price
- KPTI $5.00
- NVCT $21.00
- AVG Volume (30 Days)
- KPTI 886.0K
- NVCT 96.1K
- Earning Date
- KPTI 10-31-2024
- NVCT 11-06-2024
- Dividend Yield
- KPTI N/A
- NVCT N/A
- EPS Growth
- KPTI N/A
- NVCT N/A
- EPS
- KPTI N/A
- NVCT N/A
- Revenue
- KPTI $145,668,000.00
- NVCT N/A
- Revenue This Year
- KPTI $6.41
- NVCT N/A
- Revenue Next Year
- KPTI $11.85
- NVCT N/A
- P/E Ratio
- KPTI N/A
- NVCT N/A
- Revenue Growth
- KPTI N/A
- NVCT N/A
- 52 Week Low
- KPTI $0.62
- NVCT $5.85
- 52 Week High
- KPTI $1.95
- NVCT $12.10
- Technical
- Relative Strength Index (RSI)
- KPTI 56.22
- NVCT 52.95
- Support Level
- KPTI $0.82
- NVCT $5.90
- Resistance Level
- KPTI $0.94
- NVCT $6.53
- Average True Range (ATR)
- KPTI 0.07
- NVCT 0.33
- MACD
- KPTI 0.01
- NVCT 0.03
- Stochastic Oscillator
- KPTI 64.49
- NVCT 62.50
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.